Craig L Slingluff, Jr — Biomedical Watch V2

Traitements1programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

1

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Poly ICLCThis phase I trial studies the side effects and how well of pembrolizumab and a vaccine therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back (recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines, such as ATL-DC vaccine, may help the body build an effective immune response to kill tumor cells. Giving pembrolizumab and ATL-DC vaccine may work better in treating patients with glioblastoma compared to ATL-DC alone.	Cancer	Phase 1		United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Echopulse	Cancer	Phase 1	NCT04116320	AM-003 — Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors	TERMINATED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.